Health

AstraZeneca’s COVID-19 vaccine trial data

23 March 2021, 3:17 pm 1 minute

On March 23, Reuters was more than a minute ahead with news that leading U.S. health agency Data Safety Monitoring Board has concerns that AstraZeneca may have included outdated information on its latest COVID-19 vaccine trial.

Market Impact

The news sent AstraZeneca shares down 2% in premarket trading.

Article Tags

Topics of Interest: Health

Type: Reuters News First

Sectors: Pharmaceuticals & Healthcare

Regions: North America

Win Types: Speed

Media Types: Text

Customer Impact: Major Global Story

Share this article

Work Email Address *

Country *

I'd like to receive communications about Reuters resources, events, products, or services.

(Please note you can manage and update your preferences at any time.) By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.

By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field

Work Email Address *

Country *

More of Reuters Best

Abu Dhabi’s largest Islamic bank in talks to buy $1.1 bln stake in Indonesian lender

AstraZeneca’s COVID-19 vaccine trial data

Market Impact

More of Reuters Best

Abu Dhabi’s largest Islamic bank in talks to buy $1.1 bln stake in Indonesian lender

Billing software firm Zuora explores sale after takeover interest

Vietnam mounts ‘unprecedented’ $24 billion rescue for bank engulfed in giant fraud

Lockheed wins US missile defense contract worth $17 bln